Relief Therapeutics Holding AG (RLFTY)
USD 3.2
(6.67%)
USD 3.2
(6.67%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.29 Million CHF | -43.6% |
| 2022 | -7.56 Million CHF | 54.04% |
| 2021 | -16.45 Million CHF | -20.34% |
| 2020 | -13.67 Million CHF | -20005.88% |
| 2019 | -68 Thousand CHF | -113.33% |
| 2018 | 510 Thousand CHF | 818.31% |
| 2017 | -71 Thousand CHF | 63.78% |
| 2016 | -196 Thousand CHF | 89.27% |
| 2015 | -1.82 Million CHF | -126.83% |
| 2014 | 6.8 Million CHF | -7.01% |
| 2013 | 7.31 Million CHF | 484.49% |
| 2012 | -1.9 Million CHF | 0.0% |
| 2011 | - CHF | -100.0% |
| 2010 | 386.38 Thousand CHF | -97.19% |
| 2009 | 13.74 Million CHF | -5.53% |
| 2008 | 14.54 Million CHF | -1.9% |
| 2007 | 14.82 Million CHF | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 2.04 Million CHF | 139.81% |
| 2024 Q2 | 2.04 Million CHF | 0.0% |
| 2023 Q4 | -5.14 Million CHF | -624.76% |
| 2023 Q2 | -5.71 Million CHF | -631.01% |
| 2023 Q1 | 1.07 Million CHF | 115.84% |
| 2023 Q3 | 979.5 Thousand CHF | 117.13% |
| 2023 FY | -10.85 Million CHF | -43.6% |
| 2022 Q3 | 1.12 Million CHF | 121.6% |
| 2022 Q4 | -6.8 Million CHF | -702.3% |
| 2022 FY | -7.56 Million CHF | 54.04% |
| 2022 Q1 | 1.28 Million CHF | 141.35% |
| 2022 Q2 | -5.22 Million CHF | -506.3% |
| 2021 Q3 | 1.28 Million CHF | 0.0% |
| 2021 Q2 | - CHF | 0.0% |
| 2021 FY | -16.45 Million CHF | -20.34% |
| 2021 Q4 | -3.11 Million CHF | -342.01% |
| 2021 Q1 | - CHF | 0.0% |
| 2020 Q1 | - CHF | 0.0% |
| 2020 Q3 | - CHF | 0.0% |
| 2020 Q4 | - CHF | 0.0% |
| 2020 FY | -13.67 Million CHF | -20005.88% |
| 2020 Q2 | - CHF | 0.0% |
| 2019 Q4 | - CHF | 0.0% |
| 2019 FY | -68 Thousand CHF | -113.33% |
| 2019 Q2 | -1000.00 CHF | 0.0% |
| 2019 Q1 | - CHF | -100.0% |
| 2019 Q3 | - CHF | 100.0% |
| 2018 Q4 | 256 Thousand CHF | 0.0% |
| 2018 FY | 510 Thousand CHF | 818.31% |
| 2018 Q1 | - CHF | 100.0% |
| 2018 Q2 | - CHF | 0.0% |
| 2018 Q3 | 256 Thousand CHF | 0.0% |
| 2017 Q2 | - CHF | 0.0% |
| 2017 Q1 | - CHF | 100.0% |
| 2017 Q3 | -35.5 Thousand CHF | 0.0% |
| 2017 Q4 | -35.5 Thousand CHF | 0.0% |
| 2017 FY | -71 Thousand CHF | 63.78% |
| 2016 Q3 | -98 Thousand CHF | 0.0% |
| 2016 FY | -196 Thousand CHF | 89.27% |
| 2016 Q1 | - CHF | 0.0% |
| 2016 Q2 | - CHF | 0.0% |
| 2016 Q4 | -98 Thousand CHF | 0.0% |
| 2015 FY | -1.82 Million CHF | -126.83% |
| 2014 FY | 6.8 Million CHF | -7.01% |
| 2013 FY | 7.31 Million CHF | 484.49% |
| 2012 FY | -1.9 Million CHF | 0.0% |
| 2011 FY | - CHF | -100.0% |
| 2010 FY | 386.38 Thousand CHF | -97.19% |
| 2009 FY | 13.74 Million CHF | -5.53% |
| 2008 FY | 14.54 Million CHF | -1.9% |
| 2007 FY | 14.82 Million CHF | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 11.7 Million USD | 63.292% |
| Arch Therapeutics, Inc. | -2439.00 USD | 176278.762% |
| CSL Limited | 7.56 Billion USD | 99.943% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 96.392% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -2333.734% |
| BioStem Technologies, Inc. | 15.42 Million USD | 72.142% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 55.291% |
| Qrons Inc. | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 1444.884% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 116.656% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -6038.571% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 3558.322% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 9004.039% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -2958.363% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 98.951% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 71.351% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -138423.533% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 56.126% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -6437.549% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 12682.723% |
| Mesoblast Limited | -35.16 Million USD | 112.218% |
| Marizyme, Inc. | 457.7 Thousand USD | -838.82% |
| Genus plc | 178.7 Million USD | 97.595% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 98.048% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -6805.474% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -947.627% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 39163.636% |
| ContraFect Corporation | -154 Thousand USD | 2890.26% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 8694.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -5497.895% |
| IMV Inc. | -962.29 Thousand USD | 546.535% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 1208.9% |
| MultiCell Technologies, Inc. | 49.32 USD | -8712389.862% |
| ONE Bio Corp. | 20.12 Million USD | 78.649% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 89.328% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -8687.321% |
| Q BioMed Inc. | -8988.00 USD | 47908.189% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 84.792% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 27959.18% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 90.313% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 476.411% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 86873.021% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 4506.502% |
| GB Sciences, Inc. | -624.00 USD | 688721.795% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 5094.885% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 2065965.385% |
| Enzolytics Inc. | 30.7 Thousand USD | -13893.096% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -790.694% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.612% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 935.164% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -596.001% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 48620.777% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 5224.688% |
| Kadimastem Ltd | -630.13 Thousand USD | 781.914% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -334.927% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 36407.562% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -2333.734% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -216.621% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 14917.241% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -854.798% |
| SYBLEU INC | 11.69 Thousand USD | -36639.056% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 6.749% |
| Bioxytran, Inc. | -8285.00 USD | 51964.816% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 1252.011% |
| Neutra Corp. | 14.33 Thousand USD | -29875.584% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 5340.244% |
| PureTech Health plc | -1.6 Million USD | 368.06% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 529.17% |
| IXICO plc | 3.27 Million USD | -31.407% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 719.164% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 339.922% |
| CSL Limited | 7.7 Billion USD | 99.944% |
| Cellectis S.A. | 18 Thousand USD | -23772.222% |